Repurposing a Generic Drug in Autism Spectrum Disorder
Principal Investigator: Dr. Logan Wink
Research Description: One in 68 children is diagnosed with an Autism Spectrum Disorder (ASD). Individuals with ASD endure lifelong deficits in social communication and interaction, with restricted patterns of behavior or interests. They often also exhibit associated symptoms including hyperactivity and irritability. Historically, treatment for ASD in children has been most successful in treating these associated symptoms. To date, no medication has been shown in controlled trials to improve the core defining features of ASD. As the population of children, adolescents, and adults with ASD grows, there is a pressing medical need to develop effective and safe treatment for the core features of this disorder, thereby improving outcomes. Dr. Wink and her team will conduct a pilot clinical study of intranasal ketamine, a generic drug, in individuals with ASD to determine its effect on the core features.
Funding Partners: Anonymous
CWR funding role: Participating funder